GlassScriptPhysician profile
Christopher J Schwarz
NPI 1649319195
$11,588.03
in general payments reported to CMS, 2019-2025
41 companies · $2,409 in 2025
The $2,409 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,337 · 2020: $345 · 2021: $785 · 2022: $1,849 · 2023: $2,182 · 2024: $2,682 · 2025: $2,409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,202 · Education: $70.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,201.66 |
| Education | $70.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,148.04 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,190.85 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $872.19 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $865.04 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $654.33 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Regeneron Healthcare Solutions, INC. | $579.29 | 2022-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $478.05 | 2019-2025 | Ocaliva |
| Celgene Corporation | $343.79 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $343.36 | 2019-2025 | |
| Lilly USA, LLC | $336.26 | 2023-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $316.56 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $280.70 | 2021-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $203.44 | 2019-2024 | Dificid |
| Genzyme Corporation | $186.71 | 2023-2025 | |
| Madrigal Pharmaceuticals | $168.67 | 2024-2025 | Resmetirom, Rezdiffra |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $167.93 | 2023-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $139.80 | 2019-2025 | Rebyota, Cimzia |
| Braintree Laboratories, INC. | $133.25 | 2019 | |
| Celltrion USA INC. | $130.87 | 2024-2025 | Vegzelma, Zymfentra |
| Ipsen Biopharmaceuticals, INC | $120.62 | 2024 | Iqirvo |
| E.R. Squibb & Sons, L.L.C. | $118.30 | 2021 | |
| Evoke Pharma, INC. | $81.18 | 2023-2024 | Gimoti |
| Ironwood Pharmaceuticals, INC | $78.14 | 2019-2024 | Linzess |
| Aimmune Therapeutics, INC. | $74.17 | 2024-2025 | Zenpep |
| Janssen Pharmaceuticals, INC | $74.11 | 2019 | |
| Nestle Healthcare Nutrition INC. | $68.16 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.23 | 2024 | Ofev |
| Organon LLC | $59.73 | 2023-2024 | Renflexis |
| Redhill Biopharma INC. | $54.28 | 2020-2022 | |
| Shionogi INC | $49.70 | 2019 | |
| Alnylam Pharmaceuticals INC. | $29.95 | 2024 | Givlaari |
| Orphalan INC | $25.02 | 2025 | Cuvrior |
| Aurinia Pharma U.S., INC. | $22.21 | 2024 | Lupkynis |
| Ucb, INC. | $20.86 | 2019 | |
| Vivus LLC | $18.76 | 2024 | Qsymia |
| Mirum Pharmaceuticals, INC. | $17.33 | 2025 | Livmarli |
| Daiichi Sankyo INC. | $17.20 | 2019 | |
| Sandoz INC. | $16.59 | 2023 | Hyrimoz |
| Endo Pharmaceuticals INC. | $15.48 | 2019 | |
| Amgen INC. | $13.06 | 2023 | Tavneos, Enbrel |
| Allergan, INC. | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Schwarz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.